The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeini, M.
Right arrow Articles by Hortelano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeini, M.
Right arrow Articles by Hortelano, S.
The Journal of Immunology, 2006, 177: 3327-3336.
Copyright © 2006 by The American Association of Immunologists, Inc.

Specific Contribution of p19ARF to Nitric Oxide-Dependent Apoptosis1

Miriam Zeini*, Paqui G. Través*, Raquel López-Fontal*, Cristina Pantoja{dagger}, Ander Matheu{dagger}, Manuel Serrano{dagger}, Lisardo Boscá* and Sonsoles Hortelano2,*

* Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; and {dagger} Spanish National Cancer Center, Madrid, Spain


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
NO is an important bioactive molecule involved in a variety of physio- and pathological processes, including apoptosis induction. The proapoptotic activity of NO involves the rise in the tumor suppressor p53 and the accumulation and targeting of proapoptotic members of the Bcl-2 family, in particular Bax and the release of cytochrome c from the mitochondria. However, the exact mechanism by which NO induces p53 activation has not been fully elucidated. In this study, we describe that NO induces p19ARF through a transcriptional mechanism. This up-regulation of p19ARF activates p53, leading to apoptosis. The importance of p19ARF on NO-dependent apoptosis was revealed by the finding that various cell types from alternate reading frame-knockout mice exhibit a diminished response to NO-mediated apoptosis when compared with normal mice. Moreover, the biological relevance of alternative reading frame to p53 apoptosis was confirmed in in vivo models of apoptosis. Together, these results demonstrate that NO-dependent apoptosis requires, in part, the activation of p19ARF.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Apoptosis is a form of physiological cell death involved in development and homeostasis as well as in pathological processes such as neurodegenerative diseases and tumors (1, 2). The regulatory signals of the apoptosis cascade are extremely complex. In addition to receptor-mediated apoptosis, highly reactive molecules, such as NO, influence cell viability either by protecting against apoptogenic stimuli, or by inducing apoptosis when produced at elevated concentrations (3, 4, 5, 6). NO has been shown to up-regulate and stabilize p53, and this increase in p53 expression has been associated with increased apoptosis in several systems (4, 5, 7). Indeed, p53 transcriptionally activates a number of proapoptotic proteins, including Bax, Noxa, Puma, and Fas (8, 9). The signaling cascade induced by p53 is regulated at different levels, depending on the type of cell examined. In normal cells, p53 is expressed at low constitutive level. The latent form of p53 is stabilized and activated by posttranslational modifications, mainly multiphosphorylations and acetylation (10). Protein turnover is achieved via degradation by the 26S proteasome system, and this is mediated through the association of p53 with Mdm2 (11, 12).

An important regulator of p53 stability and activation is p19ARF. The inhibitor of cyclin-dependent kinase 4a (INK4a)3/alternative reading frame (ARF) locus encodes two unrelated proteins, p16INK4a and p19ARF, which regulate the activity of two tumor suppressors, Rb and p53, respectively (13, 14). The ARF protein (p19ARF in the mouse and p14ARF in humans) exerts its tumor suppressor action by activating the p53 pathway (15, 16). ARF controls the levels of the p53 protein due to its interaction with Mdm2, thereby interfering with Mdm2-mediated degradation of the p53 protein by the proteasome (17, 18). p19ARF exists at low or undetectable levels in most normal cells and tissue types (19). However, its expression is specifically activated by abnormal proliferative signals. These include the continued in vitro culturing of mouse embryonic fibroblasts (MEFs) (20) and the inappropriate expression of proliferative oncogenes, including activated Ras, c-myc, E2F, E1A, and v-Abl (13, 21, 22, 23). p19ARF has activities that do not depend on Mdm2 and p53. At least some of the p53-independent effects of p19ARF might be mediated by its ability to inhibit ribosomal RNA processing (24) and transcriptional factors that induce proliferation such as E2F1 (25), Myc (26), and Foxm1b (27, 28, 29). The ability of NO to induce p53 accumulation has been largely studied; however, the molecular mechanisms underlying the induction of p53 by NO have not been fully elucidated and a direct connection between NO and p19ARF has not been established. In this work, we studied the interplay between NO and p19ARF in the context of apoptosis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cell culture

Primary cultures of MEFs derived from wild-type (WT), p53–/–, and ARF–/– mice were obtained, as previously described (30, 31). Cells were maintained in DMEM supplemented with 10% FBS (Invitrogen Life Technologies) and antibiotics. MEFs were always used within their first in vitro passages (passages 1–3).

Preparation of elicited peritoneal macrophages

WT, p53–/–, and ARF–/– mice were maintained free of pathogens, and 4 days before use were i.p. injected with 1 ml of sterile 10% thioglycolate broth. Peritoneal macrophages were prepared as follows: CO2-anesthesized animals were injected i.p. with 10 ml of sterile DMEM. The peritoneal fluid was carefully aspirated to avoid hemorrhage and kept at 4°C to prevent the adhesion of the macrophages to the plastic. After centrifugation at 200 x g for 10 min at 4°C, the cell pellet was washed twice with 45 ml of ice-cold PBS. Cells were seeded at 1 x 106/cm2 in DMEM containing 10% FCS. Nonadherent cells were removed 2 h after seeding by extensive washing with medium.

Transfection assays

Cells were transiently transfected with the ARF promoter (3.4-kb genomic DNA fragment) by using Lipofectamine 2000, according to the manufacturer’s instructions. Cells were cotransfected with a Renilla luciferase expression vector to control transfection efficiency.

Flow cytometric analysis of apoptosis

Analysis of apoptotic cells was performed after incubation of the cells for 30 min at 37°C with Hoechst 33242 (5 µg/ml), a DNA-staining dye, and 0.002% propidium iodide (PI). Cells were carefully resuspended and run in a Cyan MLE-R flow cytometer (DakoCytomation), equipped with three excitation wavelengths (488, 635, and 365 nm). Quantification of the percentage of apoptotic cells was performed using a dot plot of the Hoechst 33242 fluorescence against the PI fluorescence. Apoptotic and viable cells were sorted, and the integrity of the DNA was analyzed in agarose gels to confirm the criteria of gating (32).

Preparation of cytosolic and total protein extracts

Cells were washed twice with ice-cold buffer A (10 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 1 mM DTT, 0.5 mM PMSF, 2 µg/ml aprotinin, 10 µg/ml leupeptin, 2 µg/ml N-tosyl-lys-chloromethyl ketone, 5 mM NaF, 1 mM NaVO4, and 10 mM Na2MoO4) containing 120 mM NaCl and scraped off the plate. Cells were lysed at 4°C with 0.2 ml of buffer A supplemented with 0.5% Nonidet P-40 and under continuous shaking. After centrifugation of the cell lysate, the supernatant was stored at –80°C (cytosolic extract). The presence of cytochrome c in the cytosol was determined by Western blotting cell extracts obtained by controlled lysis of the plasma membrane, as previously described (32). Total cell extracts were prepared after homogenization of the cells with buffer A supplemented with 0.5% 3-[(3-cholamidopropyl)dimethylamonio]-1-propane sulfonate. Protein content was assayed using the Bio-Rad protein reagent. All steps of cell fractionation were conducted at 4°C.

Western blot analysis of proteins

Protein extracts were size separated in 10–15% SDS-PAGE. The gels were blotted onto a Hybond-P membrane (Amersham Biosciences) and incubated with the following Abs: anti-inhibitor of apoptosis proteins (IAPs) (R&D Systems); anti-p53, anti-Bax, anti-Bcl-2, anti-Bcl-xL, anti-p16INK4a, and anti-caspases 3 and 9 (Santa Cruz Biotechnology); anti-p19ARF (AbCam ab80); and anti-cytochrome c (BD Pharmingen).

Immunocytochemistry of p19ARF

Cells grown on coverslips were fixed with methanol:acetone (1:1) at –20°C for 10 min. After washing and blocking, the coverslips were incubated with an anti-p19ARF (1 µg/ml) diluted in PBS/0.1% BSA for 1 h at room temperature. The Ab was visualized after incubation with a Cy3-labeled anti-rabbit Ig.

In vitro caspase assays

For in vitro caspase assays, cell extracts were prepared as cytosolic protein extracts. After centrifugation of the cell lysate, the supernatant was stored at –80°C (cytosolic extract), and protein content was assayed using the Bio-Rad protein reagent. The DEVDase (corresponding mainly to caspases 3 and 7), caspase 8 and caspase 9 activities were determined in cell lysates using N-acetyl-DEVD-7-amino-4-trifluoromethylcoumarin, N-acetyl-IEDT-7-amino-4-trifluoromethylcoumarin, and N-acetyl-LEHD-7-amino-4-trifluoromethylcoumarin as fluorogenic substrates and following the instructions of the supplier (Calbiochem). The corresponding peptide aldehyde and Z-VAD.fmk were used to inhibit caspase activity in vivo and to ensure the specificity of the reaction in the in vitro assay. The caspase activities were linear over a 30-min reaction period.

Real-time PCR analysis

Total RNA was isolated from cell cultures with TRIzol reagent (Invitrogen Life Technologies), and cDNA was synthesized using 50 U of Expand Reverse Transcriptase (Roche) essentially according to the recommendations of the manufacturer.

Real-time PCR was conducted with AmpliTaq Gold polymerase on an ABI Prism 7900 HT Sequence Detection system using the SyBr Green method with the following primers: 36B4 (forward primer, 5'-AGATGCAGCAGATCCGCAT-3'; reverse primer, 5'-GTTCTTGCCCATCAGCACC-3') and p19ARF (forward primer, 5'-CATGTTGTTGAGGCTAGAGAGG-3'; reverse primer, 5'-TCGAATCTGCACCGTAGTTG-3').

Tissue preparation, immunohistochemistry, and TUNEL staining

Animals were challenged with i.p. injection of 1 ml of LPS (10 µg/kg) and D-galactosamine (D-GalN) (800 mg/kg) dissolved in saline. Tissues were collected in a 30% sacarose solution in PBS and left overnight at 4°C. The samples were then frozen in 2-methylbutane at –80°C, and serial 8-µm-thick sections were cut onto gelatin-coated glass slides with a Leitz sledge microtome. The preparations were fixed for 15 min at room temperature with 4% paraformaldehyde (pH 7) in PBS and permeabilized for 2 min with 0.1% Triton X-100 in 0.1% sodium citrate. For the detection and quantification of apoptosis, the TUNEL commercial kit for cell death detection (Roche) was used, as described (33, 34). A similar protocol was used for the detection of inducible NO synthase (iNOS). After permeabilization for 15 min with cold methanol, preparations were incubated with anti-iNOS (1/50) diluted in PBS/0.1% BSA for 1 h at room temperature. The Ab was visualized using a Cy3-labeled anti-rabbit Ig. Fluorescence was analyzed and quantified on a Bio-Rad Radiance 2100 confocal microscope, with the LaserPix program. For the histological examination, 8-µm-thick sections were stained with H&E.

Enzyme activities

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were assayed in plasma using commercial kits for diagnosis (33).

Statistical analysis

The data shown are the mean ± SEM (n = 3–4). Statistical significance was estimated with Student’s t test for unpaired observations. Values of p < 0.05 and p < 0.01 were considered significant. In studies of Western blot analysis, a linear correlation between increasing amounts of input protein and signal intensity was observed (correlation coefficients, 0.84).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
NO induces apoptosis through the p19ARF-p53 pathway

NO initiates apoptosis in part by a p53-dependent pathway. Because p19ARF is among the most important regulators of p53, we studied the involvement of the p19ARF-p53 pathway in NO-dependent apoptosis. For this, primary MEFs WT, p53–/–, and ARF–/– were exposed to NO donors (S-nitrosoglutathione (GSNO), 500 µM) for 18 h, and the percentage of apoptotic cells was determined by flow cytometry. We observed that NO induced apoptosis in WT MEFs, but not in p53–/– cells, suggesting a dependence of NO apoptosis on p53 in these cells (Fig. 1A). Interestingly, when ARF–/– MEFs were treated with GSNO, the percentage of apoptotic cells was significantly reduced (Fig. 1A).


Figure 1
View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 1. NO induces apoptosis through the p19ARF/p53 pathway. Cells cultured for 18 h with 500 µM GSNO were collected and stained with 0.002% PI and Hoechst 33242 (5 µg/ml). Apoptosis was determined by flow cytometry (A). The DEVDase and LEHDase activity was determined by fluorometry in cell extracts prepared at the indicated times (B and C). The processing of caspase 9 and caspase 3 was analyzed by Western blot after stimulation with 500 µM GSNO for 8 h, whereas cytochrome c release was determined after 2 h of GSNO stimulation (D). The results show the mean ± SD of three experiments (A–C) and a representative blot of three performed (D). *, p < 0.05; **, p < 0.01 with respect to the control condition, and a, p < 0.05 and b, p < 0.01 with respect to the WT condition.

 
The central component of apoptosis is a proteolytic system involving a family of proteases called caspases (35). Analysis of caspase activation in these cells showed an important increase of caspase 3 after 6 h of GSNO treatment in WT MEFs (Fig. 1B), whereas in ARF–/– cells this activity was notably impaired and in p53–/– cells was completely abrogated. Similar results were obtained when caspase 9 activation was determined (Fig. 1C). Activation of caspase 8 was not observed in any of the experimental conditions (data not shown). In addition to these parameters, the processing of procaspase 9 and 3 was evaluated by Western blot and confirmed the previous results (Fig. 1D). NO-dependent apoptosis involves the release of mitochondrial apoptogenic factors, such as cytochrome c6. To detect whether cytochrome c release was involved in ARF-induced apoptosis, we examined its distribution in cells after treatment with GSNO for 2 h. A significant amount of cytochrome c was detected in the cytosol of WT MEFs; however, cytochrome c was not released from mitochondria in p53–/– cells (Fig. 1D). In the case of ARF–/– MEFs, cytochrome c was detected, although at lower levels than in WT cells. In view of these data, we conclude that p19ARF is involved in the apoptosis induced by NO in MEFs.

Pathways involved in ARF-dependent apoptosis

Cells were analyzed for expression of proapoptotic (Bax) and antiapoptotic (Bcl-2 and Bcl-xL) proteins of the Bcl-2 family. The amount of Bax increased after GSNO treatment in WT MEFS; however, the levels were notably lower in ARF–/– (Fig. 2). In contrast, Bax remained undetectable in p53–/– cells. When we studied the antiapoptotic members of the Bcl-2 family (Bcl-2 and Bcl-xL), NO decreased the levels of Bcl-2 and Bcl-xL in WT and ARF–/– MEFs, whereas these antiapoptotic proteins did not change in p53–/– cells (Fig. 2).


Figure 2
View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 2. p19ARF induces apoptosis through changes in the Bcl-2 family and IAPs. WT, p53–/–, and p19ARF–/– MEFS were incubated with GSNO (500 µM) and analyzed at the indicated times. The protein levels of p53, Bax, Bcl-2, Bcl-xL, and IAPs were determined by Western blot.

 
Among the most important regulators of caspases are the IAPs (36). The expression levels of the antiapoptotic proteins cIAP (cellular inhibitors of apoptosis protein)-1, cIAP-2, and X-linked IAP were determined in the different cells. cIAP-1 and cIAP-2 decreased in the presence of GSNO in WT and ARF–/– cells, although the decrease was notably lower in ARF–/– cells (Fig. 2). In contrast, X-linked IAP remained without changes in all cases. From these data we conclude that NO-induced apoptosis is mediated by decreased levels of antiapoptotic proteins, namely Bcl-2, Bcl-xL, cIAP-1, and cIAP-2, and increased levels of the proapoptotic protein Bax. All these changes are completely dependent on the function of p53 and are partially dependent on the function of p19ARF.

NO activates p53 in MEFs

To study the p53 response, the different MEFs (WT, p53–/–, and ARF–/–) were exposed to NO donors (GSNO, 500 µM) and protein levels were monitored by Western blot analysis. A significant induction of endogenous p53 was seen in WT cells. Importantly, the ablation of ARF compromised the ability of NO to promote an increase in the levels of p53, and ARF–/– cells showed a slight increase in p53 accumulation that was delayed and of lesser magnitude compared with WT cells (Fig. 2). These data imply that ARF is required, at least in part, for the activation of p53 by NO. Consistent with the above-described up-regulation of p53, the protein levels of its transcriptional target Bax varied in parallel to the changes in p53 (Fig. 2). Together, these data indicate that p19ARF plays an important role in the activation of p53 triggered by NO.

Involvement of p19ARF in NO-dependent apoptosis in macrophages

To investigate whether the involvement of p19ARF in NO-dependent apoptosis is a common pathway in other cells or is restricted to fibroblasts, we examined the effect of NO on macrophages. Primary cultures of macrophages obtained from WT, p53–/–, and ARF–/– mice were stimulated with 500 µM GSNO for 18 h, and the percentage of apoptotic cells and caspase activation were determined (Fig. 3, A, C, and D). Incubation of WT and ARF–/– macrophages with GSNO induced apoptosis, although the percentage of apoptotic cells and caspase activity in ARF–/– macrophages were significantly reduced with respect to WT macrophages. In addition to this, NO had no effect on p53–/– macrophages (Fig. 3A). Moreover, macrophages were stimulated with LPS/IFN-{gamma} to induce NOS-2 expression and NO release (6) in presence or absence of 1400W, a specific NOS-2 inhibitor. In these conditions, similar results to those obtained with GSNO were observed in WT and ARF–/– macrophages after treatment with LPS/IFN-{gamma}. Incubation of cells with LPS/IFN-{gamma} + 1400W showed that apoptosis and caspase activity remained dependent on the synthesis of NO, because they were totally suppressed by 1400W (Fig. 3, A, C, and D). We also studied the involvement of the mitochondrial pathway and the Bcl-2 family on NO-dependent apoptosis in macrophages. WT macrophages showed an important rise on cytochrome c, p53, and Bax after NO stimulation, and a decrease of Bcl-2, Bcl-xL, and IAPs (Fig. 3B). However, ARF–/– macrophages showed a diminished response. In contrast to the effect on WT macrophages, p53–/– macrophages did not change the expression of apoptotic proteins. These data suggest that the involvement of p19ARF in NO-dependent apoptosis not only occurs in fibroblasts, but also in macrophages.


Figure 3
View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 3. NO triggers apoptosis in macrophages through p19ARF induction. Macrophages obtained from WT, p53–/–, and p19ARF–/– mice were stimulated for 18 h with 500 µM GSNO or LPS (200 ng/ml) and IFN-{gamma} (50U/ml) ± 1400W (100 µM). Cells were collected and stained with 0.002% PI and Hoechst 33242 (5 µg/ml). Apoptosis was determined by flow cytometry (A). Levels of apoptotic proteins were determined by Western blot after treatment with GSNO for 6 h or LPS/IFN-{gamma} for 18 h (B). The DEVDase and LEHDase activities were determined by fluorometry in cell extracts prepared after stimulation with GSNO or LPS/IFN-{gamma}± 1400W for 18 h (C and D). The results show the mean ± SD of four experiments. *, p < 0.05; **, p < 0,01 with respect to the control condition; and a, p < 0.05 and b, p < 0.01 with respect to the WT condition.

 
NO induces p19ARF expression

To assess whether NO up-regulates p19ARF, WT, ARF–/–, and p53–/–, MEFs were incubated with 500 µM GSNO for different times and p19ARF levels were measured by immunoblotting. As Fig. 4A shows, NO induced the accumulation of p19ARF in WT and p53–/–. As a negative control, p19ARF protein was not detected on ARF–/– cells. The induction was confirmed in intact cells by immunofluorescence (Fig. 4B). Previous reports described that MEFs derived from p53–/– embryos expressed relatively high basal levels of p19ARF (14, 37). This can be appreciated at the protein level (Fig. 4, A and B); however, treatment with GSNO further augmented the levels of p19ARF protein on p53–/– cells. Similar results were obtained in macrophages. Incubation of macrophages obtained from WT animals with 500 µM GSNO for 6 h and with LPS and IFN-{gamma} for 18 h induced p19ARF accumulation. In addition, treatment with 1400W, a specific NOS-2 inhibitor, inhibited p19ARF expression after stimulation with LPS and IFN-{gamma}, indicating that p19ARF expression is dependent on NO synthesis (Fig. 4C).


Figure 4
View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 4. p19ARF increases after NO stimulation in various cell types. WT, p53–/–, and p19ARF–/– MEFS were incubated with GSNO (500 µM) and collected at the indicated times. The protein levels of p19ARF were determined by Western blot (A). MEFS were incubated with 500 µM GSNO for 4 h. p19ARF protein was detected with a specific Ab, and revealed using Cy3-labeled anti-rabbit Ig. The intensity of fluorescence was digitalized and quantified (n = 20–30 cells per condition). *, p < 0.05; **, p < 0.01 with respect to the control condition (B). Macrophages obtained from WT animals were stimulated for 6 h with 500 µM GSNO or for 18 h with LPS (200 ng/ml) and IFN-{gamma} (50U/ml) ± 1400W (100 µM). The protein levels of p19ARF were determined by Western blot (C).

 
Transcriptional up-regulation of p19ARF by NO

The changes in p19ARF expression might be due to either increased levels of p19ARF mRNA or translational and posttranslational events. To test whether the accumulation of p19ARF was attributed to increased protein stability, cells were treated with cycloheximide in the presence or absence of GSNO. As shown in Fig. 5A, exposure to GSNO had no effect on the t1/2 of p19ARF, indicating that p19ARF might be regulated at the transcription level. To evaluate this possible mechanism, we analyzed p19ARF mRNA levels by quantitative PCR. Stimulation with GSNO increased p19ARF mRNA levels in MEFs and macrophages (Fig. 5B). To confirm these results, we next examined whether other NO donors can mimic the effect of GSNO in both types of cells. We observed that Deta-NO and 3-morpholinosydnonimine (SIN-1) increased p19ARF mRNA levels in WT and p53–/– cells (Fig. 5B). These results indicate that NO is able to up-regulate p19ARF at the transcriptional level. In addition, we examined the response of ARF promoter to NO stimulation. ARF–/– MEFs were transiently transfected with ARF promoter and stimulated with NO donors (GSNO and Deta-NO). We found that NO donors activated ARF promoter, demonstrating that ARF expression is transcriptionally regulated by NO (Fig. 5E).


Figure 5
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 5. Transcriptional regulation of p19ARF. MEFS WT were incubated with 500 µM GSNO for 4 h. After NO incubation, cells were treated with cycloheximide (10 µg/ml) for the indicated times in the presence or absence of GSNO, and the levels of p19ARF were determined by Western blot (A). Cells were preincubated for 2 h with MAPK inhibitors (SB 202190, PD098059, SP 600125, 20 µM), before GSNO treatment for 4 h. Levels of p19ARF were determined by Western blot (B). Relative expression of p19ARF mRNA was determined by real-time quantitative PCR in triplicate. WT and p53–/– MEFS were incubated with different NO donors (GSNO, SIN-1, and Deta-NO, 500 µM) for 90 min (C). The same experiments were conducted with macrophages (D). Activation of ARF promoter by NO. p19ARF–/– MEFs were transiently transfected with a ARF promoter reporter plasmid (3.4 kb), in presence of NO donors (GSNO and Deta-NO, 500 µM), and luciferase activity was determined in triplicate dishes and was normalized by Renilla luciferase activity in all experiments to control for transfection efficiency. The results show the mean ± SD of three experiments (E).

 
Among the various mechanisms that activate ARF, a role for AP-1 has been recently described (38, 39). Activation of AP-1 is achieved via the MAPK pathway (40) and NO is known to activate MAPK and JNK pathways as well as AP-1 (40, 41). In this context, we explored the possible implication of MAPK pathway in the transcriptional regulation of ARF by NO. WT cells were incubated with GSNO and specific MAPK inhibitors, and levels of ARF protein were detected by Western blot. As Fig. 5C shows, MAPKs seem to play an important role on the regulation of ARF, as we can observe by the inhibition of ARF levels after treatment with p38MAPK and ERK inhibitors (SB 202190 and PD 098059, respectively).

p16INK4a is not involved in the NO-dependent apoptosis

The INK4a-ARF locus encodes two unrelated proteins, p16INK4a and p19ARF. To exclude the possible implication of p16INK4a on NO effects, we analyzed p16INK4a protein levels after treatment with NO. As Fig. 6A shows, no changes on p16INK4a protein levels were detected upon treatment with GSNO. To determine the contribution of p16INK4a to NO-dependent apoptosis, we used MEFs in which exons 2 and 3 of the INK4a/ARF locus were deleted (INK4a/ARF–/– MEFs), and therefore p16INK4a and p19ARF expression was disrupted (42) or MEFs obtained from transgenic mice (INK4a/ARF+/+;tg/· and INK4a/ARF–/–;tg/·) that contain a single copy of a genomic transgene encoding both p16INK4a and p19ARF 43. Characterization of these MEFs regarding p19ARF and p16INK4a levels is shown in Fig. 6B. As it has been described before (43), the basal levels of p16INK4a and p19ARF were moderately increased in INK4a/ARF+/+;tg/· cells; however, p16INK4a levels were not modified after treatment with GSNO. A similar increase of p19ARF was obtained on INK4a/ARF+/+ and INK4a/ARF–/–;tg/· after GSNO stimulation. Indeed, when INK4a/ARF–/– cells were incubated with GSNO for 18 h, NO did not exert any effect on apoptosis, as we have described before; however, apoptosis increased in INK4a/ARF+/+ and INK4a/ARF–/–;tg/· in a similar way (Fig. 6C). Besides, INK4a/ARF+/+;tg/· cells were more sensitive to apoptosis according to the previous reports that described that additional INK4a/ARF activity confers a generalized increased resistance to cancer (43). To confirm these results, caspase 3 activity was determined in the same conditions (Fig. 6D). As expected, DEDvase activity increased in INK4a/ARF+/+ and INK4a/ARF–/–;tg/· cells and GSNO enhanced DEVDase activity in INK4a/ARF+/+;tg/·. These data indicate that p19ARF is involved in the NO-dependent apoptosis, without participation of p16INK4a.


Figure 6
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 6. p16INK4a is not involved in NO-dependent apoptosis. WT, p53–/–, and p19ARF–/– MEFS were incubated with GSNO (500 µM) for 4 h. The protein levels of p16INK4a were determined by Western blot (A). INK4a/ARF+/+, INK4a/ARF–/–, INK4a/ARF–/–;tg/·, or INK4a/ARF+/+;tg MEFs were tested for the expression of p19ARF and p16INK4a by Western blot after treatment with 500 µM GSNO for 4 h (B). INK4a/ARF+/+, INK4a/ARF–/–, INK4a/ARF–/–;tg/·, or INK4a/ARF+/+;tg MEFs were incubated with 500 µM GSNO, and apoptosis and caspase 3 activity were determined after 18 and 8 h of treatment, respectively (C and D). **, p < 0.01 with respect to the control condition.

 
Lack of p19ARF inhibits D-GalN/LPS-induced apoptosis in an in vivo model of liver injury

To validate in vivo the involvement of p19ARF on NO-dependent apoptosis, we used an in vivo experimental model of apoptosis mediated by NO. In this model, LPS, with the additional help of D-GalN, produces a systemic activation of macrophages, which in turn secrete massive amounts of proinflammatory cytokines that activate apoptotic pathways (44). This apoptosis is mainly mediated by TNF-{alpha} and NO released by up-regulation of NOS-2 expression (45). Accordingly, mice were injected i.p. with a mixture of D-GalN and LPS, and 5 h later liver sections were examined by TUNEL staining. TUNEL-positive hepatocytes were abundantly observed in the livers of WT mice injected with D-GalN and LPS (Fig. 7A); in contrast, positively stained nuclei were rarely detected in treated ARF–/– mice (Fig. 7A). To demonstrate the involvement of NO in this model as well as ARF induction, the expression of NOS-2 was studied immunohistochemically in similar sections of treated livers and p19ARF levels were determined by Western blot. The administration of D-GalN/LPS resulted in induction of iNOS in WT and ARF–/– mice, as we can observe in Fig. 7A, whereas p19ARF expression was only detected in WT animals after D-GalN/LPS administration (Fig. 7B). Histological changes in liver tissues were investigated after H&E staining (Fig. 7A). After 5 h of D-GaIN/LPS administration, hepatocyte destruction was observed on WT animals, whereas no significant hepatic lesions were produced in livers of ARF–/– mice.


Figure 7
View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 7. Lack of p19ARF inhibits D-GalN/LPS-induced apoptosis in an in vivo model of liver injury. WT and p19ARF–/– animals were injected i.p. with LPS (10 µg/kg) and D-GalN (800 mg/kg) dissolved in 1 ml of saline solution. Animals with no treatment were injected with 1 ml of saline. Livers were removed at 5 h, and nonconsecutive liver sections were stained with Hoescht (blue) and analyzed by TUNEL (green) following the instruction of supplier. iNOS (green) was detected after staining with specific Ab by immunocytochemistry, and values of intensity fluorescence were indicated in figures (A). p19ARF levels were determined by Western blot in liver cytosolic extracts (B). Tissues were stained with H&E (A), and AST and ALT were measured in plasma (C). The caspase 3, 8, and 9 activity was determined by fluorometry in cell extracts (D). *, p < 0.05; **, p < 0.01 with respect to the control condition; and a, p < 0.05 and b, p < 0.01 with respect to the WT condition.

 
To evaluate the hepatocyte damage induced by D-GaIN/LPS, the enzymatic activities of AST and ALT were determined 5 h after i.p. administration of D-GaIN/LPS. Both AST and ALT were increased in WT animals, but not in ARF–/– mice (Fig. 7C).

Finally, to demonstrate that induction of apoptosis by D-GaIN/LPS involves caspase activation, DEVDase activity was determined in these animals, showing an increase of activity only in WT animals (Fig. 7D). These results reinforce the functional importance of ARF on NO-dependent apoptosis.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The mechanisms underlying the activation of p53 have been extensively studied (10, 46). NO-mediated apoptosis is controlled by the mitochondrial pathway with the implication that p53 accumulation is upstream of cytochrome c release.

A key regulator of p53 levels is the tumor suppressor protein ARF. ARF inhibits the p53 ubiquitin ligase, Mdm2, allowing activation of the p53 tumor suppressor (17, 18). Although the ability of NO to up-regulate p53 is well documented, much less is known about the role of p19ARF in NO-dependent apoptosis. In this study, we demonstrate that lack of ARF causes a significant decrease in the rise of apoptosis. We have found that WT MEFs and macrophages display a normal behavior after NO treatment. Thus, NO induces apoptosis in these cells through p53 up-regulation and involvement of mitochondrial mediators (changes in the expression of proteins of the Bcl-2 family, cytochrome c release, and caspase activation). However, in the absence of ARF, cells are more resistant to apoptosis, and changes on the mitochondrial proteins and caspase activation are partially abrogated, suggesting that ARF is an important contributor to the induction of apoptosis by NO. Finally, apoptosis was considerably impaired in p53–/– fibroblasts and macrophages, stressing the relevance of p53 activation in NO-induced apoptosis. In support to all these data, experiments in an in vivo model of hepatic apoptosis due to the NO generation show that lack of ARF prevents this process, providing additional evidence to the notion that induction of apoptosis by NO is mediated by ARF. Besides, all these effects are specific for ARF because the other protein encoded by the locus INK4a/ARF, p16INK4a, did not show any modification after treatment with NO. Taken together, these data indicate that NO elicits an apoptotic response mediated by the up-regulation of p19ARF, but not p16INK4a.

There is no evidence of a direct activation of p19ARF by NO. In the present study, we have shown a remarkable increase in ARF expression when cells (fibroblasts and macrophages) are incubated with NO, and we have demonstrated that p19ARF accumulation in response to NO occurs through direct transcriptional activation (mRNA increase and promoter activation), without involvement of protein stabilization. Unlike a prior report that shows ARF activation in response to SIN-1, a peroxynitrite donor (47), we have established that not only exogenous NO induces ARF, but proinflammatory stimuli such as LPS and IFN-{gamma} promote ARF activation via NO. Studies in macrophages obtained from WT mice clearly demonstrate the involvement of NO in ARF activation as reflected by its inhibition after treatment with 1400W, a NOS inhibitor. Moreover, NO-dependent apoptosis was lower in ARF–/– macrophages than in WT macrophages, and was totally abrogated when cells were incubated with 1400W, the NOS inhibitor, in the presence of LPS and IFN-{gamma}. These data clearly establish a relationship between NO and ARF expression. In addition to this, our data show a reduced activation of p53 by NO in the absence of ARF at early times (4–8 h). This reduction was even observed with low concentrations of GSNO (100–200 µM) (data not shown). These results contradict those published by Wang et al. (48), whose studies reported that NO neither uses the ARF tumor suppressor protein nor ataxia telangiectasia-mutated (ATM) to accumulate p53. However, it is important to take into account that these experiments were conducted with a high concentration of GSNO (1 mM vs 100–500 µM) and for a long period of time (10 h), and at this time we have also observed p53 activation (Fig. 2). Moreover, high concentrations of NO (in millimolar range) can increase mitochondrial reactive oxygen species production, and oxidative stress is known to be a potent activator of p53. In addition to our results, the involvement of ATM on p53 accumulation was recently questioned by demonstrating that phosphorylation of p53 at serine 15 after NO treatment is ATM and ATM- and Rad3-related (ATR) dependent (49, 50).

In view of these results, it is not possible to exclude p19ARF as an important contributor to NO-induced p53 accumulation, although it is worthwhile to mention that there are ARF-independent pathways that activate p53. Between them, the inhibition of NF-{kappa}B through a mechanism that does not require either p53 or Mdm2 has recently been described. ARF represses the transcriptional activation domain of the NF-{kappa}B family member RelA by inducing its association with the histone deacetylase, HDAC1. Moreover, ARF activates the ATR/Chk1 pathway, and this is required for its ability to both repress RelA and induce p53. Therefore, the presence of ARF could determine the sensitization of the cells to apoptosis through the inhibition of NF-{kappa}B trans activation (51, 52). Indeed, we cannot rule out that NF-{kappa}B might play a role in the NO-dependent apoptosis induced through ARF, because the involvement of ATM/ATR in the phosphorylation of p53 after NO treatment has been described recently (49, 50). Nevertheless, NO stimulation provides a more complex scenery, because NO has direct effects on Mdm2. Indeed, p53 accumulation upon treatment with NO is preceded by a decrease in Mdm2 protein levels; however, extended exposure to NO augmented the levels of Mdm2 due to the activation of the mdm2 gene by p53 (48, 53). In this context, experiments with ARF-deficient cells to determine NO-induced changes in Mdm2 might establish the significance of Mdm2 in this process; however, no significant differences on Mdm2 protein levels were observed in ARF-deficient cells vs WT cells after NO treatment (data not shown), indicating that at least in our model, additional experiments must be required to elucidate the contribution of p53-dependent and independent mechanisms to the NO-induced apoptosis.

To gain insight on mechanism by which NO leads to ARF activation, we are analyzing the transcriptional activity of the ARF promoter that seems to be subjected to a rather complex regulation, probably requiring the combined action of several transcription factors. A large number of nuclear factors have been implicated in this process, such as Sp-1, DMP-1, E2F, and AP-1. Preliminary results demonstrated that treatment with MAPK inhibitors, especially with p38MAPK and ERK inhibitors, prevented the up-regulation of p19ARF by NO, indicating a possible involvement of this pathway in the ARF activation (Fig. 8). However, the relevance of this mechanism requires further investigation.


Figure 8
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 8. Proposed model for the mechanism involved in ARF activation by NO. Exposure to NO induces p53 up-regulation leading to apoptosis. In normal cells, MDM2 maintains low levels of p53 by targeting the protein for degradation by the proteasome (dashed lines). MDM2 activity is counteracted by ARF, which prevents the MDM2-mediated degradation of p53. NO increases ARF transcription and protein levels through a mechanism that seems to involve MAPK pathways and possibly AP-1 activation.

 
In conclusion, the results presented in this work describe for the first time the involvement of ARF in NO-dependent apoptosis as a universal mechanism observed in various cell types and model animals. Moreover, we have provided evidence for the transcriptional regulation of ARF by NO. Therefore, the novel pathway we describe in this study is an important component of NO-dependent apoptosis and contributes to unraveling the apoptotic activity of NO.


   Acknowledgments
 
We thank Gemma Benito and Maribel Muñoz for their excellent technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was funded by the Ministerio de Educación y Ciencia (SAF2002-0083) and by Fundació La Caixa (ONO3-180-2). M.Z. is funded by Community of Madrid; P.G.T. is supported by a Beca de Formación en Investigación fellowship from Instituto de Salud Carlos III; and R.L.-F. is supported by a Formación de Profesorado Universitario fellowship from the Spanish Ministry of Education and Science. S.H. is a Fondo de Investigaciones Sanitarias program investigator and is supported by Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I), and Instituto de Salud Carlos III with a project Fondo de Investigaciones Sanitarias (2002/3022) and PI05.0050 (2005). Back

2 Address correspondence and reprint requests to Dr. Sonsoles Hortelano, Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro 3, 28029 Madrid, Spain. E-mail address: shortelano{at}cnic.es Back

3 Abbreviations used in this paper: INK4a, inhibitor of cyclin-dependent kinase 4a; ARF, alternative reading frame; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ATM, ataxia telangiectasia-mutated; ATR, ATM and Rad3 related; cIAP, cellular inhibitors of apoptosis protein; D-GalN, D-galactosamine; GSNO, S-nitrosoglutathione; IAP, inhibitor of apoptosis protein; iNOS, inducible NO synthase; MEF, mouse embryonic fibroblast; PI, propidium iodide; WT, wild type; SIN-1, 3-morpholinosydnonimine. Back

Received for publication February 21, 2006. Accepted for publication May 22, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Thompson, C. B.. 1995. Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1144. [Abstract/Free Full Text]
  2. Green, D. R.. 1998. Apoptotic pathways: the roads to ruin. Cell 94: 695-694. [Medline]
  3. Bosca, L., S. Hortelano. 1999. Mechanisms of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators. Cell. Signal. 11: 239-244. [Medline]
  4. Hortelano, S., P. G. Traves, M. Zeini, A. M. Alvarez, L. Bosca. 2003. Sustained nitric oxide delivery delays nitric oxide-dependent apoptosis in macrophages: contribution to the physiological function of activated macrophages. J. Immunol. 171: 6059-6064. [Abstract/Free Full Text]
  5. Hortelano, S., A. Castrillo, A. M. Alvarez, L. Bosca. 2000. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165: 6525-6531. [Abstract/Free Full Text]
  6. Hortelano, S., A. M. Alvarez, L. Bosca. 1999. Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages. FASEB J. 13: 2311-2317. [Abstract/Free Full Text]
  7. Messmer, U. K., B. Brune. 1996. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem. J. 319: 299-305. [Medline]
  8. Yu, J., L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, B. Vogelstein. 1999. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. USA 96: 14517-14522. [Abstract/Free Full Text]
  9. Villunger, A., E. M. Michalak, L. Coultas, F. Mullauer, G. Bock, M. J. Ausserlechner, J. M. Adams, A. Strasser. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038. [Abstract/Free Full Text]
  10. Prives, C., P. A. Hall. 1999. The p53 pathway. J. Pathol. 187: 112-114. [Medline]
  11. Jimenez, G. S., S. H. Khan, J. M. Stommel, G. M. Wahl. 1999. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18: 7656-7665. [Medline]
  12. Sionov, R. V., Y. Haupt. 1999. The cellular response to p53: the decision between life and death. Oncogene 18: 6145-6157. [Medline]
  13. Serrano, M.. 1997. The tumor suppressor protein p16INK4a. Exp. Cell Res. 237: 7-4. [Medline]
  14. Quelle, D. E., F. Zindy, R. A. Ashmun, C. J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000. [Medline]
  15. Prives, C.. 1998. Signaling to p53: breaking the MDM2–p53 circuit. Cell 95: 5-4. [Medline]
  16. Sherr, C. J.. 2001. The INK4a/ARF network in tumor suppression. Nat. Rev. Mol. Cell Biol. 2: 731-734. [Medline]
  17. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, G. Peters. 1998. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014. [Medline]
  18. Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, et al 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92: 713-723. [Medline]
  19. Zindy, F., R. T. Williams, T. A. Baudino, J. E. Rehg, S. X. Skapek, J. L. Cleveland, M. F. Roussel, C. J. Sherr. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. USA 100: 15930-15935. [Abstract/Free Full Text]
  20. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659. [Medline]
  21. De Stanchina, E., M. E. McCurrach, F. Zindy, S. Y. Shieh, G. Ferbeyre, A. V. Samuelson, C. Prives, M. F. Roussel, C. J. Sherr, S. W. Lowe. 1998. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev. 12: 2434-2244. [Abstract/Free Full Text]
  22. Palmero, I., C. Pantoja, M. Serrano. 1998. p19ARF links the tumor suppressor p53 to Ras. Nature 395: 125-124. [Medline]
  23. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433. [Abstract/Free Full Text]
  24. Sugimoto, M., M. L. Kuo, M. F. Roussel, C. J. Sherr. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11: 415-414. [Medline]
  25. Martelli, F., T. Hamilton, D. P. Silver, N. E. Sharpless, N. Bardeesy, M. Rokas, R. A. DePinho, D. M. Livingston, S. R. Grossman. 2001. p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. USA 98: 4455-4460. [Abstract/Free Full Text]
  26. Qi, Y., M. A. Gregory, Z. Li, J. P. Brousal, K. West, S. R. Hann. 2004. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717. [Medline]
  27. Kalinichenko, V. V., M. L. Major, X. Wang, V. Petrovic, J. Kuechle, H. M. Yoder, M. B. Dennewitz, B. Shin, A. Datta, P. Raychaudhuri, R. H. Costa. 2004. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 18: 830-850. [Abstract/Free Full Text]
  28. Kuo, M. L., E. J. Duncavage, R. Mathew, W. den Besten, D. Pei, D. Naeve, T. Yamamoto, C. Cheng, C. J. Sherr, M. F. Roussel. 2003. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 63: 1046-1053. [Abstract/Free Full Text]
  29. Suzuki, H., M. Kurita, K. Mizumoto, I. Nishimoto, E. Ogata, M. Matsuoka. 2003. p19ARF-induced p53-independent apoptosis largely occurs through BAX. Biochem. Biophys. Res. Commun. 312: 1273-1277. [Medline]
  30. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-4. [Medline]
  31. Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, S. W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602. [Medline]
  32. Hortelano, S., M. Zeini, A. Castrillo, A. M. Alvarez, L. Bosca. 2002. Induction of apoptosis by nitric oxide in macrophages is independent of apoptotic volume decrease. Cell Death Differ. 9: 643-650. [Medline]
  33. Mojena, M., S. Hortelano, A. Castrillo, M. J. Diaz-Guerra, M. J. Garcia-Barchino, G. T. Saez, L. Bosca. 2001. Protection by nitric oxide against liver inflammatory injury in animals carrying a nitric oxide synthase-2 transgene. FASEB J. 15: 583-585. [Abstract/Free Full Text]
  34. Hortelano, S., M. Zeini, L. Bosca. 2002. Nitric oxide and resolution of inflammation. Methods Enzymol. 359: 459-454. [Medline]
  35. Shi, Y.. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9: 459-454. [Medline]
  36. Salvesen, G. S., C. S. Duckett. 2002. IAP proteins: blocking the road to death’s door. Nat. Rev. Mol. Cell Biol. 3: 401-404. [Medline]
  37. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95: 8292-8297. [Abstract/Free Full Text]
  38. Ameyar-Zazoua, M., M. B. Wisniewska, L. Bakiri, E. F. Wagner, M. Yaniv, J. B. Weitzman. 2005. AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene. Oncogene 24: 2298-2306. [Medline]
  39. Sreeramaneni, R., A. Chaudhry, M. McMahon, C. J. Sherr, K. Inoue. 2005. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol. Cell. Biol. 25: 220-232. [Abstract/Free Full Text]
  40. Robinson, M. J., M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9: 180-184. [Medline]
  41. Pilz, R. B., M. Suhasini, S. Idriss, J. L. Meinkoth, G. R. Boss. 1995. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J. 9: 552-558. [Abstract]
  42. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, R. A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-24. [Medline]
  43. Matheu, A., C. Pantoja, A. Efeyan, L. M. Criado, J. Martin-Caballero, J. M. Flores, P. Klatt, M. Serrano. 2004. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev. 18: 2736-2746. [Abstract/Free Full Text]
  44. Galanos, C., M. A. Freudenberg, W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76: 5939-5943. [Abstract/Free Full Text]
  45. Morikawa, A., Y. Kato, T. Sugiyama, N. Koide, D. Chakravortty, T. Yoshida, T. Yokochi. 1999. Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosamine-sensitized mice as an experimental endotoxic shock model. Infect. Immun. 67: 1018-1024. [Abstract/Free Full Text]
  46. Woods, D. B., K. H. Vousden. 2001. Regulation of p53 function. Exp. Cell Res. 264: 56-54. [Medline]
  47. Kaji, T., I. Kaieda, T. Hisatsune, S. Kaminogawa. 2002. 3-Morpholinosydnonimine hydrochloride induces p53-dependent apoptosis in murine primary neural cells: a critical role for p21ras-MAPK-p19ARF pathway. Nitric Oxide 6: 125-134. [Medline]
  48. Wang, X., D. Michael, G. de Murcia, M. Oren. 2002. p53 activation by nitric oxide involves down-regulation of Mdm2. J. Biol. Chem. 277: 15697-15702. [Abstract/Free Full Text]
  49. Hofseth, L. J., S. Saito, S. P. Hussain, M. G. Espey, K. M. Miranda, Y. Araki, C. Jhappan, Y. Higashimoto, P. He, S. P. Linke, et al 2003. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA 100: 143-148. [Abstract/Free Full Text]
  50. Goodman, J. E., L. J. Hofseth, S. P. Hussain, C. C. Harris. 2004. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ. Mol. Mutagen. 44: 3-9. [Medline]
  51. Rocha, S., K. J. Campbell, N. D. Perkins. 2003. p53- and Mdm2-independent repression of NF-{kappa}B transactivation by the ARF tumor suppressor. Mol. Cell 12: 15-25. [Medline]
  52. Rocha, S., M. D. Garrett, K. J. Campbell, K. Schumm, N. D. Perkins. 2005. Regulation of NF-{kappa}B and p53 through activation of ATR and Chk1 by the ARF tumor suppressor. EMBO J. 24: 1157-1169. [Medline]
  53. Schneiderhan, N., A. Budde, Y. Zhang, B. Brune. 2003. Nitric oxide induces phosphorylation of p53 and impairs nuclear export. Oncogene 22: 2857-2868. [Medline]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
S. Lim, A. C. Hung, and A. G. Porter
Focused PCR Screen Reveals p53 Dependence of Nitric Oxide-Induced Apoptosis and Up-Regulation of Maspin and Plasminogen Activator Inhibitor-1 in Tumor Cells
Mol. Cancer Res., January 1, 2009; 7(1): 55 - 66.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeini, M.
Right arrow Articles by Hortelano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeini, M.
Right arrow Articles by Hortelano, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS